Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease

Curr Drug Targets. 2015;16(9):976-87. doi: 10.2174/1389450116666150416114514.

Abstract

Cystic fibrosis (CF) is a deadly genetic disease that affects the lungs and digestive system. A mutation in the CF transmembrane conductance regulator (CFTR) gene is the cause of the disease. How epigenetics contributes to CFTR expression is still poorly understood. Epigenetics is a mechanism that alters gene expression without changing the underlying DNA sequence. Epigenetic mechanisms include DNA methylation and histone modification. Both mechanisms have been implicated in CFTR gene regulation. Here we review epigenetic regulation of CFTR transcription while discussing potential epigenetic targeting strategies including DNA methyltransferase, histone deacetylase, and histone methyltransferase and demethylase inhibition. Because of the reversibility of epigenetics, targeting epigenetic mechanisms has been an attractive therapeutic approach. However, epigenetic targeting of CF disease is still at its infant stage.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / enzymology
  • Cystic Fibrosis / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
  • DNA Modification Methylases / antagonists & inhibitors
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Epigenesis, Genetic / drug effects*
  • Histone Deacetylases
  • Histone Methyltransferases
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Mutation

Substances

  • CFTR protein, human
  • Enzyme Inhibitors
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • DNA Modification Methylases
  • Histone Methyltransferases
  • Histone-Lysine N-Methyltransferase
  • Histone Deacetylases